

**DOUGLAS A. HOLT, MD, FACP, FIDSA**  
**University of South Florida, Morsani College of Medicine, Tampa, Florida**

**Address:**

Professor, Division of Infectious Disease and International Medicine  
1 Tampa General Circle  
Tampa, FL 33606  
(813) 844-8297

Director, Florida Department of Health – Hillsborough County  
P.O. Box 5135  
Tampa, Florida 33675-5135  
(813) 307-8008

**Citizenship:**

USA

**Medical Licensure:**

1985 Florida, ME46949

**Education:**

1980-1984 MD, University of South Alabama, College of Medicine, Mobile, Alabama  
1976-1980 BS, Davidson College, Davidson, North Carolina, 1980

**Postgraduate Training:**

1987-1989 Fellow, Division of Infectious Diseases and Tropical Medicine, USF,  
Morsani College of Medicine, Tampa, FL  
1984-1987 Resident, Internal Medicine, USF, Morsani College of Medicine, Tampa,  
FL

**Board Certifications:**

American Board of Internal Medicine – Infectious Disease. 2017-27  
American Board of Internal Medicine

National Board of Medical Examiners

**Editorial Activities:**

Editor, Florida Department of Health -Hillsborough County COVID-19 Case Surveillance and Vaccine Report, 2020-present

Editor, Florida Department of Health – Hillsborough County EpiNotes Newsletter, 2012-present

Editor, USFID@yahoogroups.com, 2010 – present

Editor, IDPodcasts.net, 2007 - present

Editor, Southern Medical Association Dial Access Program, 1992-1997

Associate Editor, Contagion, 1993

Reviewer, Infections in Medicine, 1994-2009

Reviewer, Infections in Urology, 1994-2001

**Honors & Awards:**

- |              |  |
|--------------|--|
| 2014         | Barness/Behnke Chapter, Gold Humanism Honor Society, USF, Tampa, FL  |
| 2013         | Alpha Omega Alpha Honor Medical Society, Gamma Chapter, USF, Tampa, FL   |
| 2012         | Distinguished Service to State of Florida; Executive Office of Governor, Rick Scott  |
| 2009         | University of South Florida, Area Community Civic Association, Inc., Edwin Radice Distinguished Service Award for Community Commitment (Outreach in "Suitcase City") |
| 2007-present | Best Doctors in America®   |
| 2007-2009    | USF, Morsani College of Medicine, Appreciation Award, Faculty Secretary  |
| 2006         | Leadership Award for active involvement in the leadership Institute and for demonstrated commitment to excellence in leadership                                      |
| 2004         | USF College of Public Health Outstanding Partner Award, Florida Center for Public Health Preparedness  |
| 2003         | USF Lifetime Appreciation Award from USF Infectious Disease Faculty  |
| 2003         | Tampa Fire Rescue, Appreciation Award  |
| 2001         | State of Florida, Commendation, Dedicated Service and Outstanding  |

### Leadership

- |           |   |
|-----------|---|
| 2001      | Hillsborough County Board of County Commissioners, Certificate of Appreciation  |
| 2000      | School District of Hillsborough County, Excellence in Education   |
| 2000      | Outstanding Community Service Award, University of Tampa, School of Nursing, Tampa, FL  |
| 1993-2000 | I had to turn focus inward to re-organize research efforts and re-organize Florida Department of Health as acting Deputy Secretary                |
| 1993      | Outstanding Teaching Award, Critical Care Medicine Program, Department of Surgery and Anesthesiology, USF, Morsani College of Medicine, Tampa, FL |
| 1992      | Attending Physician Award, Protective Care Unit, Tampa General Hospital, Tampa, Florida (Compassionate Care)                                      |
| 1992      | Outstanding Teaching Award, Critical Care Medicine Program, Department of Surgery and Anesthesiology, USF, Morsani College of Medicine, Tampa, FL |
| 1990      | President's Circle of Excellence Award, Tampa General Hospital, Tampa, FL   |
| 1987      | Ciba-Geigy Outstanding Resident Award, USF, Morsani College of Medicine, Tampa, FL  |

### Continuing Professional Education:

- |           |   |
|-----------|---|
| 2006      | USF Leadership Institute: Inaugural Class   |
| 2005-2006 | Leadership Florida Program: Class XXIV  |
| 2001-2002 | Graduate, National Public Health Leadership Institute, Centers for Disease Control: Class X |

### Appointments:

#### Academic:

- |              |   |
|--------------|---|
| 2019-present | Courtesy Professor, College of Public Health, University of South Florida, Tampa, FL  |
| 2012-2019    | Director, Division of Infectious Disease and International Medicine, Department of Internal Medicine, USF, Morsani College of Medicine, Tampa, FL |
| 2011-2019    | Endowed Professorship, Andor Szentivanyi Professor, USF, Morsani College of Medicine, Tampa, FL   |

- 2003-present Professor, Division of Infectious Disease and International Medicine, Department of Internal Medicine, USF, Morsani College of Medicine, Tampa, FL
- 1997-present Associate Professor, (adjunct appointment) Department of Pediatrics, USF, Morsani College of Medicine, Tampa, FL
- 1994-2003 Associate Professor, Division of Infectious Diseases and Tropical Medicine, Department of Internal Medicine, USF, Morsani College of Medicine, Tampa, FL
- 1991-1996 Program Coordinator, Tampa General Hospital, Division of Infectious Diseases and Tropical Medicine, Department of Internal Medicine, USF, Morsani College of Medicine, Tampa, FL
- 1989-1994 Assistant Professor, Division of Infectious Diseases and Tropical Medicine, Department of Internal Medicine, USF, Morsani College of Medicine, Tampa, FL

**Hospital:**

- 2015-2016 Englewood Community Hospital – Telemedicine Consultant
- 1989-present Attending Physician, Tampa General Hospital
- 1989-2019 Attending Physician, Shriner’s Crippled Children’s Hospital
- 1989-2004 Attending Physician, H. Lee Moffitt Cancer Center

**Other:**

- 2014-2020 Chief of Infectious Disease Section, Tampa General Hospital, Tampa, FL
- 2012-2013 Vice-Chief of the Section of Internal Medicine, Tampa General Hospital, Tampa, FL
- 2011-2012 Acting Deputy State Health Officer, Florida Department of Health
- 2005-2020 Assistant Medical Director, Infection Prevention, Tampa General Hospital, Tampa, FL
- 2004-2012 Associate Director, Division of Infectious Disease and International Medicine, Morsani College of Medicine, USF, Tampa, FL
- 2001-2002 Acting Deputy State Health Officer, Florida Department of Health
- 1996-present Director, Florida Department of Health – Hillsborough County, Tampa, FL (I am one of two full-time faculty members in the US to Direct the Health Department – others are Medical Directors)

1995-1996	Chief of Medical Staff, Florida Department of Health – Hillsborough County, Tampa, FL
1991-1996	Hospital Epidemiologist, Tampa General Hospital, Tampa, FL
1989-1993	Medical Director, Protective Care Unit, Tampa General Hospital, Tampa, FL (Helped start the first HIV care unit in West Florida)
1989-1991	Assistant Hospital Epidemiologist, Tampa General Hospital Tampa, FL

### Teaching, Lectures:

#### Undergraduate Medical:

2014-2018	BMS 6890 - SELECT Professional Development
2010-present	Capstone Lectures, College of Public Health, USF
1994-present	MEL 8362 - Attending, Infections in Cancer and Bone Marrow Transplant Patients
1992-present	MEL 8363 - Course Director, Infections in the ICU Patient
1992-present	MEL 8364 - Course Director, Clinical Epidemiology of Infectious Diseases
1990-present	MEL 8365 - Attending, Outpatient Care of the HIV Infected Patient
1990-1996	ANA 7761 - Lecturer, Critical Care Team, Department of Anesthesiology
1989-present	BMS 6810 - Lecturer, Introduction to Clinical Medicine
1989-present	BCC 6110 - Attending, Internal Medicine Clerkship
1989-present	MEL 8310 - Course Director, Infectious Disease and Tropical Medicine
1989-present	MEL 8357-03 - Attending, Infections in Transplant Medicine
1989-present	MEL 9910 - Attending, Independent Study in Infectious Diseases

#### Graduate Medical:

1989-present	Fellowship, Infectious Disease and International Medicine, USF Morsani College of Medicine
1989-present	Resident, Internal Medicine – Infectious Disease rotation, USF Morsani College of Medicine

**Other Teaching:**

- 2014 Mentor, Patient Centered Care at the Speed of Trust, Tampa General Hospital, Tampa, FL
- 1988-1996 Group Lecture Director, Bay Area Epidemiologist Florida Practitioners in Infection Control, Tampa, FL

**Lectures by Invitation:**

Speed of Trust, LEAD Hospital Administrator's Training Program, USF Medicine International, Tampa, FL, 2018

Organizational Accountability, LEAD Hospital Administrator's Training Program, USF Medicine International, Tampa, FL, 2017

*C. difficile* – Quality Improvement, Medical Directors Meeting, Tampa General Hospital, Tampa, FL, 2017

Organizational Accountability, LEAD Hospital Administrator's Training Program, USF Medicine International, Tampa, FL, 2016

Zika Update, Tampa Bay Immunization Summit, Tampa General Hospital, Tampa, FL, 2016

Zika Virus: Threat and Response, Zika Symposium, USF Morsani College of Medicine, Tampa, FL, 2016

Zika Update, Zika at Our Doorstep: An International Public Health Conversation, University of South Florida, Tampa, FL, 2016

Public Health: The Health Department Perspective, presentation to Capstone Students, USF College of Public Health, Tampa, FL, 2016

Emerging Vector-Borne Diseases: Dengue, Chikungunya & Zika, National Public Health Week sponsored by USF College of Public Health, Tampa, FL, 2016

Emerging Viral Infections: Chikungunya, MERS-CoV, Measles, and Ebola, presentation to the Infectious Disease Interest Group (IDIG), USF Morsani College of Medicine, Tampa, FL, 2015

Organizational Accountability, LEAD Hospital Administrator's Training Program, USF Medicine International, Tampa, FL, 2015

Public Health: The Health Department Perspective, presentation to Capstone Students, USF College of Public Health, Tampa, FL, 2015

Organizational Accountability, LEAD Hospital Administrator's Training Program, USF Medicine International, Tampa, FL, 2015

Emerging Viral Infections: Ebola, Enterovirus D69, and Chikungunya, Lee Memorial Health System, Ft. Myers, FL, 2015

Public Health 101, Leadership Tampa, Tampa, FL, 2015

Ebola, Executive Board of the Tampa Bay Region Private-Public Partnership, Tampa, FL, 2014

Ebola, USF Ebola CE Conference, USF Health, Tampa, FL, 2014

Ebola – Coming to America: Fact, Fiction & Fear, Internal Medicine Grand Rounds, USF Morsani College of Medicine, Tampa, FL, 2014

Ebola – Fears and Facts, Board of Trustees Workgroup, USF Health, Tampa, FL, 2014

Ebola – Coming to America: Fact, Fiction & Fear, Leadership Tampa, Tampa, FL, 2014

Organizational Accountability, LEAD Hospital Administrator's Training Program, USF Medicine International, Tampa, FL, 2013

### **Published Bibliography:**

#### **Refereed Publications:**

1. Somboonwit C, Menezes LJ, Holt DA, Sinnott JT, Shapshak P. Current views and challenges on clinical cholera. *Bioinformation* 13(12):405-409, Dec 2017. [ISSN 0973-2063(online), PMID: 29379258]
2. JP Morano, DA Holt. The social determinants of health contextualized for the Zika virus. *Int J Infect Dis* 65:142-143, Dec 2017, Epub 2017 Nov 16  
<https://doi.org/10.1016/j.ijid.2017.10.006>, [PMID: 29081365]
3. Hauser RA, Furtado S, Cimino CR, Delgado H, Eichler S, Schwartz S, Scott BA, Nauert GM, Soety E, Sossi V, Holt DA, Sanberg PR, Stoessl AJ, Freeman TB: Bilateral human fetal striatal transplantation in Huntington's disease, *Neurology* 58: 687-695, 2002
4. Lartz BW, Narvarte HJ, Holt D, Larkin JA, Pomputius WF. Congenital tuberculosis and management of exposures in a neonatal intensive care unit. *Infection Control and Hospital Management* 23(10): 573-9, 2002
5. Ganguly R, Holt DA, Sinnott JT: Exposure of Medical Students to Body Fluids, *The Journal of American College Health*, 47:207, 1999
6. Nadler JP, Oehler RL, Holt DA: Update of Antiretroviral Therapy For HIV Infection, *Infections in Medicine* 15:113,1998
7. Freeman TB, Olanow CW, Hauser RA, Nauert M, Smith DA, Borlongan CV, Sanberg PR, Holt DA, Kordower JH, Vingerhoets FJG, Snow BJ, Calne D, Gauger BS: Bilateral Fetal Nigral Transplantation into the Postcommissural Putamen in Parkinson's Disease, *Annals of Neurology* 38:379, 1995
8. Holt DA, Nauert MG, Othberg AI, Randall TS, Willing AE, Widen RH, Hauser RA, Sanberg PR, Olanow CW, Freeman TB: Infectious Issues In Fetal Neural Transplantation, *Cell Transplantation*, 6:553, 1997
9. Holt DA, Larkin JA: Continuing Issues in Ventilator-Associated Pneumonia. *Infections in Medicine*, 12:12, 1995

10. Holt DA, Baran DA, Sinnott JT, Oehler RL: Delta Hepatitis: Diagnostic Algorithms. *Infections in Medicine*, 10:23, 1993
11. DiTomaso A, Warner EA, Holt DA, Ritrosky S: Toxic Shock Syndrome Arising "De Novo" from Cellulitis. *American Journal of Medical Sciences*, 308:110, 1994
12. Clenney TL, Hammond MD, McKeown PP, Holt DA, Wallach PM: Cardiac Tamponade due to *Nocardia Asteroides*. *Chest*, 103:641, 1993
13. Esperanza L, Holt DA, Sinnott JT, Cancio MR, Bradley EA, Deutsch M, Murine Typhus: Forgotten but Not Gone. *Southern Medical Journal*, 85: 754, 1992
14. Holt DA, Sinnott JT, Oehler RK, Baran DA: Relapsing Fever: Ticked off by a Lousy Illness. *Infections in Medicine*, 9:18, 1992
15. Holt DA, Sinnott JT, Oehler RL, Bradley EA: BK Virus. *Infection Control and Hospital Epidemiology*, 13:738, 1992
16. Holt DA, Sinnott JT, Bradley EA: Nosocomial Prostatitis. *Infections in Urology*, 5: 139, 1992
17. Hill DA, Sinnott JT, Holt DA, Cancio MR: A Patient Who Got Darker on Zidovudine Therapy. *Hospital Practice*, 27:29, 1992
18. Holt DA, Albers SE, Sinnott JT: Post Anginal Sepsis with Dysphagia. *Southern Medical Journal*, 84:385, 1991
19. Holt DA, Pattani NJ, Sinnott JT, Bradley EA: Lyme Borreliosis. *Infection Control and Hospital Epidemiology*, 12:493, 1991
20. Lynch CM, Sinnott JT, Holt DA, Herold AH: The Use of Antibiotics During Pregnancy. *American Family Physician*, 43:1365, 1991
21. Larkin J, Sinnott JT, Weiss J, Holt, DA: Human T-Cell Lymphotropic Virus-Type I. *Infection Control and Hospital Epidemiology*, 11:314, 1990
22. Sinnott JT, Alvarez C, Greene J, Sweeney MJ, Holt DA: *Nocardia Brasiliensis* Cellulitis in a Heart Transplant Patient. *Texas Heart Institute Journal*, 17:133, 1990
23. Sinnott JT, Holt DA: Cryptococcal Pyarthrosis Complicating Gouty Arthritis. *Southern Medical Journal*, 82:155, 1989
24. Sinnott JT, Cullison JP, Sweeney MS, Holt DA: Respiratory Syncytial Virus Pneumonia in a Cardiac Transplant Patient. *The Journal of Infectious Diseases*, 158:650, 1988

**Non-Refereed Publications:**

1. Addisu A, Aslam S, Holt DA, Alrabaa S, Casanas B. Changing Patterns of HIV-TB Coinfection Among Patients in a Public Health Department Ambulatory Care Setting: A 50Year Experience from a US Metropolitan Area. *Open Forum Infectious Disease*, 2018 Nov; 5 (Suppl 1): S458. Pub online 2018 Nov 26. doi: 10.1093/ofid/ofy210.1311
2. Sinnott JT, Van Sant SP, Holt DA, Behnke RH, Lipp K: A Medical History Timeline. *Florida Medical Society, Journal Florida Medical Association*, 2:121, 1993



3. Emmanuel PJ, Holt DA, Ganguly R: HTLV-I Associated Myelopathy. Infectious Disease Newsletter, 10:4, 1991
4. Sinnott JT, Esperanza L, Holt DA, Thompson F: Hantavirus. Infectious Disease Newsletter, 10:51, 1991
5. Lynch CM, Holt DA, Sinnott JT: Human Parvovirus B19 and Pregnancy. Infectious Disease Newsletter, 10:87, 1991
6. Holt DA, Sinnott JT, Prieto J: Human Herpes Virus-6. Infectious Disease Newsletter, 9:17, 1990
7. Sinnott JT, Carballo FE, Holt DA, Rubin RW: An Introduction to Organ Transplantation. Infectious Disease Newsletter, 8:34, 1989

#### **Textbook Chapters:**

1. Kynaston K, Casanas B, Holt DA. Chapter CNS Tuberculosis and HIV Infection. In Shapshak P, Singer E, Levine A, Sinnott JT, Somboonwit C. Global Virology II: HIV and NeuroAIDS. New York, Springer, 2017. In press.
2. Freeman TB, Olanow CW, Hauser RA, Kordower JH, Holt DA, Borlongan CV, Sanberg PR: Human Fetal Tissue Transplantation, Neurosurgical Treatment of Movement Disorders, The American Association of Neurological Surgeons Chapter 13, 177-192, 1998
3. Holt DA, Haight DO: "Fever of Unknown Origin" In H. Neu (ed): Current Practice of Medicine, Philadelphia 1996
4. Sinnott JT, Holt DA: "Fever of Unknown Origin" In H. Neu (ed): Current Practice of Medicine, Philadelphia 1993
5. Holt DA: A Practical Approach to Infectious Diseases by Reese R., Betts R., 6:77,1992

#### **Abstracts:**

##### **(Associated with Research Studies)**

1. Holt DA, co-investigator, Casanas B, PI, A Phase IIIb, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of a Single Tablet Regimen of Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Compared with a Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment Naïve Adults [Gilead GS-US-264-0110 – February 2011]
2. Holt DA, co-investigator, Casanas B, PI, A Phase 3 Randomized, Open-Label Study to Evaluate Switching from Regimens Consisting of a Ritonavir-boosted Protease Inhibitor and Two Nucleoside Reverse Transcriptase Inhibitors to Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF) Fixed-dose Regimen in Virologically-Suppressed, HIV-1 Infected Patients [Gilead GS-US-264-0106 February 2011]

3. Holt DA, co-investigator, Casanas B, PI, An open-label trial with TMC278 25 mg q.d. in combination with a background regimen containing 2 nucleoside/nucleotide reverse transcriptase inhibitors in HIV-1 infected subjects, who participated in TMC278 clinical trials [Protocol: TMC278-TiDP6-C222 – January 2011]
4. Holt DA, co-investigator, Montero J, PI, An Open-Label, Extension Safety Trial of Pregabalin in Subjects with Neuropathic Pain Associated with HIV Neuropathy (PREGABALIN Pfizer A0081251 December 2010)
5. Holt DA, co-investigator, Somboonwit C, PI, Strategic Timing of AntiRetroviral Treatment (START February 2009)
6. Holt DA, co-investigator, Somboonwit C, PI, A Pilot, Randomized, Controlled Study to Evaluate the Safety and Efficacy of Raltegravir versus NRTIs as a Backbone in HIV-Infected Patients Switched from a Stable Boosted PI Regimen [IISP – 33107 January 2009 (Merck)]
7. Kneer C, Bradley EA, Poblete SA, Sinnott JT, Holt DA, Ganguly: Practice of Universal Precautions Guidelines (UVPG) in Occupational Settings. Infectious Diseases Society of America 36th Annual Meeting, 1998
8. Larkin JA, Houston SH, Holt DA, Sinnott JT, Oehler R, Alexander LA: Reduction in Contaminated Allograft Bone Cultures by a Tissue Handling Protocol. The Southern Section, American Federation for Medical Research, New Orleans, Louisiana, 1997
9. Ganguly R, Marty P, Herold A, Desai V, Anderson M, Sinnott JT, Holt DA, Larkin JA, Quiroz E, Callahan C, Mbaga I: Hepatitis B Virus Vaccine Cost: A Barrier to Immunization. The 97th American Society for Microbiology, Miami Beach, Florida, 1997
10. Ganguly R, Toney JT, Holt DA, Sinnott JT, Carney M, Cobian L, Desai V: Occupational Risks of Hepatitis B Virus Infection Among Older Health Care Providers (HCP). 1997 Research Day, Office of Research and Graduate Affairs News, University of South Florida Morsani College of Medicine, Tampa, Florida, 1997
11. Ganguly R, Marty P, Herold A, Desai V, Anderson J, Sinnott JT, Holt DA, Larkin JA, Quiroz E, Callahan C, Mbaga I: Hepatitis B Virus Vaccine Cost: A Barrier to Immunization. The 97th American Society of Microbiology, Miami Beach, Florida, 1997
12. Ganguly R, Sinnott JT, Houston SH, Toney JT, Holt DA, Cobian L: Hepatitis B Virus Vaccine: A Measure against occupationally acquired infection. The 35th Annual Meeting of the Infectious Disease Society of America, San Francisco, California, 1997
13. Sinnott JT, Holt DA, Houston SH: Clarithromycin as Prophylaxis for MAC Disease--A Follow up Review. 3rd International Conference on the Macrolides Azalides and Streptogramins, Lisbon, Portugal, 1996
14. Houston S, Holt D, Sinnott J, Oehler R, Larkin L, Alexander: Reduction in Contaminated Allograft Bone Cultures by a Tissue Handling Protocol. 36th ICAAC Conference, New Orleans, Louisiana 1996
15. Nadler JP, Toney JT, Holt DA, Seeley P; Toxicities in Patients Receiving Retrovir, HIVID, and Interferon-Alfa for HIV Infection. Proceedings of 6th International Congress for Infectious Diseases, Prague, Czech Republic, 1994

16. Nadler JP, Toney JF, Holt DA, Seeley P: Comparison of Retrovir, HIVID, and Wellferon versus Retrovir and Hivid in HIV Infected Patients without AIDS. 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, Louisiana, 1993
17. Nadler JP, Toney, JT, Holt DA, Seeley P, Comparison of Retrovir, HIVID, and Wellferon versus Retrovir and HIVID in HIV Infected Patients Without AIDS. Interscience Conference on Antimicrobial Agents and Chemotherapy, October, 1993
18. Seeley P, Toney JT, Holt DA; Development of a Newsletter to Provide New Information to Study Participants in a Long-Term HIV Clinical Trial. 6th Annual Conference of the Association of Nurses in HIV Care, Los Angeles, CA, 1993
19. Ragsdale RL, Holt DA, Houston SH, Widen RH: Polymerase Chain Reaction for Confirmation of Parvovirus B19 Infection. Clinical Virology Symposium, Clearwater, Florida, 1993
20. Toney JF, Sinnott JT, Holt DA: Chlamydia One dose Treatment with Azithromycin. American Society for Clinical Investigation, American Federation for Clinical Research, 40:2 Baltimore, Maryland, May, 1992
21. Holt DA, Houston SH, Sinnott JT, Alexander LA, and Oehler RA: The Correlation of Cadaveric Blood Cultures with Bone Cultures. 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, California, October, 1992
22. Holt DA, Houston SH, Sinnott JT, Alexander LA, Oehler RL: The Correlation of Cadaveric Blood Cultures with Bone Cultures. 16th Annual Meeting of American Association of Tissue Banks, San Diego, California, 1992
23. Cancio M, Mayer C, Sinnott J, Holt DA: A Simplified Approach to Controlling Methicillin-Resistant Staphylococcus aureus with Hibiclens and Mupirocin in a Chronic Ventilatory Care Facility. American College of Physicians, Tampa, Florida 1992
24. Hein SA, Markowsky SJ, Dillon KR, Holt DA, and Rosemurgy AS: Impact of Pharmacotherapy Services on Intravenous Fluconazole Utilization. 27th Annual American Society of Hospital Pharmacists Midyear Clinical Meeting, Orlando, Florida, 1992
25. Sinnott JT, Holt DA, Smith JH, Widen RH, Tanaka A, Cichon M: Immunophenotype of Peripheral Blood Cells from Chronic Fatigue Syndrome Patients. American College of Physicians Scientific Meeting, (Poster Presentation) Orlando, Florida, 1991
26. Sinnott JT, Holt DA: Nutritional Perceptions of AIDS Patients, American College of Physicians Scientific Meeting, Florida Chapter, Tampa, Florida, 1990
27. Holt DA, Rosemurgy AS, Finney R, Cameron D, Ganguly R, Sinnott JT, An Alternative Central Access Device in HIV Positive Patients. American College of Physicians, - Scientific Session, Tampa, Florida, 1990
28. Ganguly R, Russell D, Sinnott JT, Fuller S, Holt DA, Cameron DJ: Practice and Perception Among Patients with HIV Infection. American College of Nutrition, Scarsdale, NY, 1989

**Miscellaneous Creative Works:**

1. Zika Updates, USF Health, 2014 - present
2. Ebola Updates, USF Health, Aug 2014 – Jan 2015
3. TB System of Care, Florida Department of Health, 2014
4. Holt DA: Penicillins and Imipenem, Southern Medical Association Dial Access Program, 1994
5. Holt DA: AIDS: Epidemiology and Pathogenesis, Southern Medical Association Dial Access Program, 1994
6. Holt DA: AIDS: Pneumocystis carinii Pneumonia, Southern Medical Association Dial Access Program, 1994
7. Holt DA: Coccidioidomycosis, Southern Medical Association Dial Access Program, 1994
8. Holt DA: Endocarditis: Diagnosis and Therapy, Southern Medical Association Dial Access Program, 1994
9. Holt DA: Tuberculosis Policy, Tampa General Hospital, 1993
10. Holt DA: Body Substance Isolation, Tampa General Hospital, 1992
11. Holt DA: OSHA Manual: Exposure to Blood Borne Disease, Tampa General Hospital, 1992
12. Holt DA: Varicella Exposure, Tampa General Hospital, 1992
13. Holt DA; Exposure to Meningitis: What to Do? Tampa General Hospital, Tampa, Florida, 1992
14. Sinnott JT, Holt DA: Fellows Manual, Division of Infectious Diseases, Department of Internal Medicine, University of South Florida, Morsani College of Medicine 1991-present (annual revisions)
15. Holt DA; In-service examination, Division of Infectious Diseases and Tropical Medicine, Department of Internal Medicine, University of South Florida, Morsani College of Medicine, 1991, Revised 1992, 1998, 2002

**Sponsored Projects and Contracts**

I hold an Executive level Department of Health position that is appointed by the Governor. Serving as PI requires pre-approval from the Surgeon General. This process is very time consuming and delays submission to the IRB. Therefore, I decided it was best to offer the role of PI to my faculty – consistent with my aim to develop both my faculty and the Division's research.

### **Ongoing Sponsored Projects and Contracts**

Amgen 20130286 USF award 6123-8146 Funded: \$116,005 Life to date earnings: \$10,500 A Double Blind, Randomized, Placebo Controlled, Multicenter Study to Evaluate Safety, Tolerability, and Efficacy on LDL-C of Evolocumab (AMG 145) in Subjects with HIV and with Hyperlipidemia and/or Mixed Dyslipidemia. Role: Co-Investigator	PI: Morano, J	03/27/2017 – present
Gilead GS-US-380-4458 Funded for: \$80,000 A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment Naïve HIV-1 and Hepatitis B Co-Infected Adults. Role: Co-Investigator	PI: Morano, J	04/2018 – present
Florida DOH 7ZK19 USF award 6123-1207 Funded for: \$1,117,413 University of South Florida Integrated Clinical Trial Network Structuring and Enhancement for Execution of Zika Virus Vaccine and Diagnostic Clinical Trials, and testing of other Emerging Infectious Disease (EID) Solutions for Florida Role: Co-Investigator	PI: Casale, TB	03/02/2017 – 03/31/2020
Gilead Sciences Funded for: \$ 384,813 FOCUS: Frontlines of Communities in the United States. Opt-out Testing for HIV and Hepatitis C in Tampa General Hospital Emergency Department and Implementation of Innovative Linkage to Care Programs at FL-DOH Hillsborough Role: Co-Investigator	PI: Wilson, J	5/1/2017 – present
Merck MK-966151439-018 USF award 6123-8102 Funded: 143,644 Life to date earnings: \$48,420 A Phase 3 Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Doravirine (MK-1439) 100 mg Once Daily Versus Darunavir 800 mg Once Daily plus Ritonavir 100 mg Once Daily, Each in Combination with TRUVADA™ or EPZICOM™/KIVEXA™ in treatment of HIV-1 Infected Subjects. Role: Co-Investigator	PI: Montero, J	01/29/2015 – present
Florida DOH HB378 USF award 6123-1230 Fixed price: \$445,024/y USF Physician Oversight and Research Coordination	PI: Holt, DA	07/01/2018- 6/30/2019
Florida Department of Health USF auxiliary account fund 01547 Fixed price contract: \$205,560/y Role: Co-Investigator	PI: Choe, U	2013 – present

Institute for Clinical Research Inc. PI: Somboonwit, C 03/01/2009– present  
ICR award M22-TA-032-0907-3 (federal flow through NIAID)  
USF award 6123-1084  
Life to date earnings: \$367,887  
Strategic Timing of Antiretroviral Treatment (START)  
Role: Co-Investigator

Florida Department of Health PI: Holt, DA 1999 – present  
USF auxiliary account fund 01547  
Fixed price contract: \$216,828/y  
Role: Co-Investigator

### **Completed Sponsored Projects and Contracts**

GlaxoSmithKline 204862 TANGO PI: Casanas, B 1/2018 – 6/2018  
Funded: 85,578  
A Phase III, Randomized, Multicenter, Parallel-group, Non-inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Dolutegravir plus Lamivudine in HIV-1 Infected Adults Who are Virologically Suppressed.

Florida DOH HB335 PI: Holt, DA 07/01/2014- 06/30/2018  
USF award 6123-1143  
Fixed price: \$445,024/y  
USF Physician Oversight and Research Coordination

Gilead GS-US-366-1216 PI: Wills, T 03/16/2015 – 02/28/18  
USF award 6123-8107  
Life to date earnings: \$49,572  
A Phase 3b, Randomized, Double-Blind Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide Fixed Dose Combination in HIV-1 Positive Subjects who are Virologically-Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate.  
Role: Co-Investigator

Gilead GS-US-366-1160 PI: Wills, T 03/16/2015 – 2/28/18  
USF award 6123-8106  
Life to date earnings: \$121,271  
A Phase 3b, Randomized, Double-Blind Study to Evaluate Switching from a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination to Emtricitabine/ Rilpivirine/ Tenofovir Alafenamide FDC in Virologically-Suppressed, HIV-1 Infected Subjects.  
Role: Co-Investigator

Gilead Sciences PI: Wilson, J 4/1/2016 – 3/31/2017  
Funded for: \$ 416,912  
FOCUS: Frontlines of Communities in the United States. Opt-out Testing for HIV and Hepatitis C in Tampa General Hospital Emergency Department and Implementation of Innovative Linkage to Care Programs at FL-DOH Hillsborough  
Role: Co-Investigator

Gilead GS-US-311-1089 PI: Wills, T 06/20/2014 – 02/25/2015  
USF award 6123-8090  
Life to date earnings: \$8,850  
A Phase 3, Randomized, Open-Label, Switch Study to Evaluate F/TAF in HIV-1 Positive Subjects Who are Virologically Suppresses on Regimens Containing FTC/TDF.  
Role: Co-Investigator

Florida DOH HB313 PI: Holt, DA 07/01/2013 – 06/30/2014  
USF award 6123-1119  
Fixed price: \$447,524  
USF Physician Oversight and Research Coordination

Gilead GS-US-292-0112 PI: Wills, T 05/21/2013 – 12/12/2016  
USF award 6123-8070  
Life to date earnings: \$157,370  
A Phase 3, Open-Label Safety Study of Elvitegravir/Cobicistat/ Emtricitabine/ Tenofovir Alafenamide Single-Tablet Regimen in HIV-1 Positive Patients with Mild to Moderate Renal Impairment.  
Role: Co-Investigator

Gilead GS-US-292-0111 PI: Wills, T 02/18/2013 – 10/17/2016  
USF award 6123-8067  
Life to date earnings: \$62,371  
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults.  
Role: Co-Investigator

Gilead GS-US-292-0109 PI: Wills, T 05/30/2013 – 08/15/2016  
USF award 6123-8068  
Life to date earnings: \$137,267  
A Phase 3, Open-Label Study to Evaluate Switching from a TDF-Containing Combination Regimen to a TAF-Containing Combination Single Tablet Regimen (STR) in Virologically Suppressed, HIV-1 Positive Subjects.  
Role: Co-Investigator

Merck MK-1439-007 PI: Montero, J 03/22/2013 – 09/16/2016  
USF award 6123-8047  
Life to date earnings: \$23,362  
Multicenter, Double-Blind, Randomized, 2-Part, Dose Ranging Study to Compare the Safety, and Antiretroviral Activity of MK 1439 Plus TRUVADA™ Versus Efavirenz Plus TRUVADA™ in Antiretroviral Treatment-Naïve, HIV-1 Infected Patients.  
Role: Co-Investigator

Gilead GS-US-292-0119 PI: Wills, T 11/05/2013 – 07/13/2016  
USF award 6123-8078  
Life to date earnings: \$26,140  
A Phase 3, Open-Label Study to Evaluate Switching from Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/ Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF)Single Tablet Regimen (STR) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults.  
Role: Co-Investigator

EMD Serono, Inc. EMR200147-500 PI: Somboonwit, C 02/25/2013 – 02/02/2015  
USF award 6123-8057

Life to date earnings: \$8,200

A Prospective, Randomized, Placebo-Controlled, Double-Blind Clinical Trail to Evaluate whether EGRIFTA® (tesamorelin for injection), 2 mg Once Daily SC, Increases the Risk of Development or Progression of Diabetic Retinopathy when Administered to HIV-Infected Subjects with Abdominal Lipohypertrophy and Concomitant Diabetes.

Role: Co-Investigator

GSK ING117172 PI: Casanas, B 10/02/2013 – 04/13/2015  
USF award 6123-8075

Life to date earnings: \$12,739

A Phase IIIb, Randomized, Open-Label Study of the Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine Once Daily Compared to Atazanavir and Ritonavir Plus Tenofovir/Emtricitabine Once Daily in HIV-1 Infected Antiretroviral Therapy Naïve Women.

Role: Co-Investigator

Gilead GS-US-292-0117 PI: Wills, T 11/05/2013 – 05/26/2015  
USF award 6123-8076

Life to date earnings: \$6,450

A Phase 3, Two Part Study to Evaluate the Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment with Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1 Positive, Antiretroviral Treatment-Experiences Adults.

Role: Co-Investigator

Gilead GS-US-292-0104 PI: Wills, T 02/04/2013 – 10/13/2014  
USF award 6123-8066

Life to date earnings: \$29,017

A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults.

Role: Co-Investigator

Merck 96615 PI: Somboonwit, C 02/13/2013 – 08/04/2014  
USF award 6123-8064

Life to date earnings: \$3,540

Quality of Life of HIV-Infected Patients Switched to Raltegravir Versus other Antiretroviral Regimens.

Role: Co-Investigator

Pfizer A4001095 PI: Montero, J 10/11/2011 – 10/08/2014  
USF award 6123-8024

Life to date earnings: \$47,547

A Multicenter, Randomized, Double Blind, Comparative Trial of Maraviroc + Darunavir/Ritonavir versus Emtricitabine/Tenofovir +Darunavir/Ritonavir For The Treatment Of Antiretroviral-Naive HIV Infected Patients with CCR5 Tropic HIV-1.

Role: Co-Investigator



Gilead GS-US-264-0106                      PI: Casanas, B                      03/08/2011 – 10/19/2012  
USF award 6123-8008  
Life to date earnings: \$12,333  
A Phase 3 Randomized, Open-Label Study to Evaluate Switching from Regimens Consisting of a Ritonavir-boosted Protease Inhibitor and Two Nucleoside Reverse Transcriptase Inhibitors to Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF) Fixed-dose Regimen in Virologically-Suppressed, HIV-1 Infected Patients.  
Role: Co-Investigator

Pfizer A4001098                      PI: Wills, T                      06/30/2011 – 10/02/2012  
USF award 6123-8006  
Life to date earnings: \$18,125  
A Multicenter, Randomized, Blinded, Placebo-Controlled Study To Evaluate The Safety Of Maraviroc In Combination With Other Antiretroviral Agents In HIV-1-Infected Subjects Co-Infected With Hepatitis C and/or Hepatitis B Virus.  
Role: Co-Investigator

Gilead GS-US-183-0144                      PI: Wills, T                      10/03/2008 – 10/02/2013  
USF Research Foundation A673DF  
Life to date earnings: \$103,853  
A Multicenter, Randomized, Double-blind, Double-dummy, Phase 3 Study of the Safety and Efficacy of Ritonabir-Boosted Elvitegravir (RVG/r) versus Raltegravir (RAL) Each Administered with a Background Regimen in HIV-1 Infected, Antiretroviral Treatment-Experienced Adults.  
Role: Co-Investigator

Gilead GS-US-236-0102                      PI: Wills T                      05/03/2010 – 05/02/2015  
USF Research Foundation A673EJ  
Life to date earnings: \$65,367  
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Emtricitabine/Tenofovir Disoproxil Fumarate/GS-9350 versus favirenz/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV 1 Infected, Antiretroviral Treatment-Naïve Adults.  
Role: Co-Investigator

Gilead GS-US-216-0114                      PI: Wills, T                      06/17/2010 – 2014  
USF Research Foundation A673EQ  
Life to date earnings: \$76,784  
A Phase 3, Randomized, Double-Blind, Study to Evaluate the Safety and Efficacy of GS-9350-boosted Atazanavir Versus Ritonavir-boosted Atazanavir. Each Administered with Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults.  
Role: Co-Investigator

Gilead GS-US-236-0103                      PI: Wills, T                      05/03/2010 – 05/02/2015  
USF Research Foundation A673EK  
Life to date earnings: \$98,209  
Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Emtricitabine/Tenofovir Disoproxil Fumarate/GS-9350 Versus Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults.  
Role: Co-Investigator

Pfizer A5271038 PI: Montero, J 09/15/2009 – 09/14/2012  
USF Research Foundation A673ED  
Life to date earnings: \$3,500  
A Phase 2B/3 Open-Label Rollover Study for Subjects Discontinuing from the UK-453,061  
Protocols for the Treatment of HIV-1 Infected Subjects.  
Role: Co-Investigator

Pfizer A0081244 PI: Montero, J 05/03/2010 – 06/30/2011  
USF Research Foundation A673EI  
Life to date earnings: \$6,250  
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Trial of  
Pregabalin Versus Placebo in the Treatment of Neuropathic Pain Associated with HIV  
Neuropathy.  
Role: Co-Investigator

Gilead GS-US-164-0216 PI: Kurtyka, D 04/21/2009 – 04/20/2014  
USF Research Foundation A673DN  
Life to date earnings: \$9,162  
The SWIFT Study: A Prospective, Randomized, Open-Label Phase IV Study to Evaluate the  
Rationale of Switching from Fixed Dose Abacavir (ABC)/Lamivudine (3TC) to Fixed-Dose  
Tenofovir DF (TDF)/Emtricitabine (FTC) in Virologically-Suppressed, HIV-1 Infected Patients  
Maintained on a Ritonavir-Boosted Protease Inhibitor-Containing Antiretroviral Regimen.  
Role: Co-Investigator

Schering-Plough P04875 PI: Somboonwit, C 03/26/2009 – 03/25/2014  
USF Research Foundation A673DL  
Life to date earnings: \$239,173  
Efficacy and Safety of VICRIVIROC in HIV Infected Treatment-Naïve Subjects  
Role: Co-Investigator

Pfizer A4001078 PI: Montero, J 03/18/2009 – 03/17/2014  
USF Research Foundation A673DO  
Life to date earnings: \$269,153  
Pilot Study of Novel Combination of Maraviroc + Atazanavir/Ritonavir Vs.  
Atazanavir/Ritonavir + Emtricitabine/Tenofovir for the Treatment of Treatment Naïve HIV-  
Infected Patients with R5 HIV-1.  
Role: Co-Investigator

Pfizer A5271022 PI: Montero, J 09/15/2009 – 07/15/2011  
USF Research Foundation A673EC  
A Phase 2B Multicenter, Randomized, Comparative Trial of UK-453,061 Versus Etravirine In  
Combination With Darunavir/Ritonavir And A Nucleotide/Nucleoside Reverse Transcriptase  
Inhibitor For The Treatment Of Antiretroviral Experienced HIV-1 Infected Subjects With  
Evidence of NNRTI Resistant HIV-1.  
Role: Co - Investigator

Florida DOH PI: Holt, DA 07/01/2009-06/30/2013  
Contract (UMSA)  
Fixed price: \$447,524  
USF Physician Oversight and Research Coordination

Merck IISP – 33107 PI: Somboonwit, C 06/19/2008 – 08/31/2010  
USF Research Foundation A673CG  
A Pilot, Randomized, Controlled Study to Evaluate the Safety and Efficacy of Raltegravir versus NRTIs as a Backbone in HIV-Infected Patients Switched from a Stable Boosted PI Regimen.  
Role: Co-Investigator

Tibotec TMC278-TiPD6-C209 PI: Casanas, B 06/24/2008 – 06/23/2013  
USF Research Foundation A673CK  
Life to date earnings: \$95,050  
A Phase III, randomized, double-blind trial of TMC278 75mg q.d. versus efavirenz 600 mg q.d. in combination with fixed dose background regimen consisting of tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naïve HIV-1 infected subjects.  
Role: Co-Investigator

Schering Plough-P04889 PI: Somboonwit, C 06/19/2007 – 06/18/2012  
USF Research Foundation A673BZ  
Life to date earnings: \$84,765  
Vicriviroc in Combination Treatment with an Optimized ART Regimen in HIV-Infected Treatment-Experienced Subjects.  
Role: Co-Investigator

Kendle / Napo Pharma – NP303-101 PI: Casanas, B 07/18/2007 – 07/17/2012  
USF Research Foundation A673BP  
Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Two-Stage Study to Assess the Efficacy and Safety of Crofelemer 125mg, 250 mg, and 500 mg Orally Twice Daily for the Treatment of HIV-Associated Diarrhea.  
Role: Co-Investigator

Tibotec-TMC114-C229 PI: Wills, T 01/16/2008 – 01/15/2013  
USF Research Foundation A673CI  
A randomized, open-label trial to compare the efficacy, safety and tolerability of DRV/rtv (800/100 mg) q.d. versus DRV/rtv (600/100 mg) b.i.d. in early treatment-experienced HIV-1 infected subjects.  
Role: Co-Investigator

GlaxoSmithKline – EPZ108859 PI: Montero, J 05/31/2007 – 08/20/2009  
USF Research Foundation A673BQ  
Safety and Efficacy of an Initial Regimen of Atazanavir + Ritonavir + the Abacavir/Lamivudine Fixed-Dose Combination Tablet for 36 weeks followed by Simplification to Atazanavir with the Abacavir/Lamivudine Fixed-Dose Combination Tablet or Maintenance of the Initial Regimen for an Additional 48 weeks in Antiretroviral-Naïve HIV-1 Infected HLA-B\*5701 Negative Subjects.  
Role: Co-Investigator

Paragon Biomedical / Abbott M06-802 PI: Casanas, B 11/29/2006 – 11/28/2009  
USF Research Foundation A673AW  
Life to date earnings: \$5,500  
A Phase 3, Randomized, Open-label Study of Lopinavir/ritonavir Tablets 800/200 mg Once-daily Versus 400/100 mg Twice-daily when Co-administered with Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Antiretroviral-experienced, HIV-1 Infected Subjects.  
Role: Co-Investigator

Tibotec TMC125-C206 PI: Wills, T 02/14/2006 – 02/13/2011

USF Research Foundation A673Y9

Life to date earnings: \$68,226

A Phase III randomized, double-blinded, placebo-controlled trial to investigate the efficacy, tolerability and safety of TMC125 as part of an ART including TMC114/RTV and an investigator-selected OBR in HIV-1 infected subjects with limited to no treatment options.

Role: Co-Investigator

Tibotec TMC114-C202 PI: Montero, J 01/05/2004 – 01/04/2007

USF Research Foundation A673P5

Phase II Randomized, Controlled, Partially Blinded Trial to Investigate Dose Response of TMC114/RTV in 3-Class Experienced HIV-1 Infected Subjects, Followed by an Open-Label Period on the Recommended Dose of TMC114/RTV.

Role: Co-Investigator

Gilead GS-US-183-0105 PI: Wills, T 04/12/2006 – 04/11/2011

USF Research Foundation A673AA

Life to date earnings: \$28,702

A Phase 2, Randomized Study of the Treatment of Antiretroviral Treatment-Experienced, HIV-1 Infected Subjects Comparing Ritonavir-Boosted GS-9137 (GS-9137/r) Versus a Comparator Ritonavir-Boosted Protease Inhibitor (CPI/r) in Combination with a Background Antiretroviral Therapy.

Role: Co-Investigator

Achillion Pharm. ACH443-015 PI: Somboonwit, C 06/28/2006 – 06/27/2012

USF Research Foundation A673AL

A Phase II, Randomized, Blinded, 12-Week Comparison of Elvucitabine in Combination with Efavirenz and Tenofovir Versus Lamivudine in Combination with Efavirenz and Tenofovir in HIV-1 Infected, Treatment-Naïve Subjects, with a 12-Week Extension Treatment Period.

Role: Co-Investigator

Pfizer A4001027 PI: Wills, T 2005 - 2011

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of a Novel CCR5 Antagonist, UK-427,857, in Combination with Optimized Background Therapy versus Optimized Background Therapy alone for the Treatment of Antiretroviral-Experienced HIV-1 Infected Subjects.

Role: Co-Investigator

Tibotec TMC278-204 PI: Casanas, B 06/21/2005 – 06/20/2013

USF Research Foundation A673W1

Life to date earnings: \$105,363

A Phase IIb, Randomized, Partially Blinded, Dose-Finding Trial of TMC278 in Antiretroviral Naïve HIV-1 Infected Subjects.

Role: Co-Investigator

Tibotec TMC114-C211 PI: Somboonwit, C 02/14/2006 – 02/13/2011

USF Research Foundation A673Z4

Life to date earnings: \$22,880

A randomized, controlled, open-label trial to compare the efficacy, safety and tolerability of TMC114/ritonavir versus lopinavir/ritonavir in treatment-naïve HIV-1 infected subjects. This trial will be referred to as ARTEMIS.

Role: Co-Investigator

Tibotec TMC125-C229 PI: Casanas, B 10/19/2005 – 10/18/2010  
USF Research Foundation A673W5  
An Open-Label Trial with TMC125 in HIV-1 Infected Subjects, Who Were Randomized to a TMC125 Treatment Arm in a Sponsor-Selected TMC125 Trial and were Treated for at least 48 Weeks.  
Role: Co-Investigator

GSK EPZ104057 – HEAT PI: Casanas, B 06/01/2005 – 05/08/2008  
USF Research Foundation A673V6  
Life to date earnings: \$128,886  
A 96-Week, Phase IV, Randomized, Double-Blind, Multicenter Study of the Safety and Efficacy of Epzicom Versus Truvada Administered in Combination with Kaletra in Antiretroviral-Naive HIV-1 Infected Subjects.  
Role: Co-Investigator

GSK COL100758 PI: Casanas, B 04/14/2005 – 04/13/2010  
USF Research Foundaiton A673U8  
Life to date earnings: \$69,135  
A Randomized, Prospective Study of the Efficacy, Safety and Tolerability of Two Doses of GW433908/Ritonavir Given with Abacavir/Lamivudine Fixed Dose Combination.  
Role: Co-Investigator

Tibotec TMC114-C214 PI: Montero, J 07/14/2005 – 07/13/2008  
USF Research Foundation A673X0  
A Randomized, Controlled, Open-Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV versus LPV/RTV in Treatment-Experienced HIV-1 Infected Subjects.  
Role: Co-Investigator

Tibotec MC125-C223 PI: Nadler, J 07/15/2004 – 07/14/2007  
Award TMC125-C223  
A randomized, controlled, partially blinded Phase IIb dose-finding trial of TMC125, in HIV-1 infected subjects with documented genotypic evidence of resistance to currently available NNRTIs and with at least three primary PI mutations.  
Role: Co-Investigator

SMART CPCRA 065 PI: Somboonwit, C 2003 - 2008  
A Large, Simple Trial Comparing Two Strategies for Management of Anti-Retroviral Therapy.  
Role: Co-Investigator

Merck 032 PI: Holt, DA 07/25/2007 – 07/24/2009  
USF Research Foundation A673CC  
Life to date earnings: \$4,800  
A Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 Versus KALETRA in HIV-Infected Patients Switched From a Stable KALETRA Based Regimen – Study A.

Tibotec Pharmaceuticals Ltd. TMC114-C226 PI: Nadler, J 05/03/2006 – 12/31/2006  
USF Research Foundation A673AF  
Life to date earnings: \$2,500  
Early Access of TMC114 in Combination with Low-Dose Ritonavir (RTV) and Other Antiretrovirals (ARVs) in Highly Treatment Experienced HIV-1 Infected Subjects with Limited or No Treatment Options.  
Role: Co-Investigator

A Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 Versus KALETRA in HIV-Infected Patients Switched From a Stable KALETRA Based Regimen – Study A.

Health and Human Services                      PI: Holt, DA                      2004-2009  
Steps to a Healthier Hillsborough County  
Life to date earnings: \$7,400,000

Merck V520-014                      PI: Holt, DA                      09/03/2002 – 04/30/2008  
USF Research Foundation A673J4  
Life to date earnings: \$24,358  
A Probe Study to Evaluate the Safety, Tolerability, and Immunogenicity of the MRK Adenovirus Serotype 5 Vector (MRKAd5) Human Immunodeficiency Virus Type I (HIV-1) gag Vaccine in HIV-1 Infected Individuals.  
Role: Co-Investigator

Health and Human Services                      PI: Jeffers, D                      1997-2001  
Life to date earnings: \$10,000,000  
Hillsborough Healthy Start Program  
Role: Co-Investigator

Florida Department of Health                      PI: Jeffers, D                      1997-1999  
Life to date earnings: \$230,000  
Maternal Child Health Outcome Indicators in Public Health Clinic  
Role: Co-Investigator

Florida Department of Health                      PI: Studnicki, J                      1997  
Life to date earnings: \$150,000  
Hillsborough County Community Health Assessment  
Role: Co-Investigator

Hillsborough County Public Health Unit                      PI: Larkin, JA                      1996  
Life to date earnings: \$1,000,000  
Housing and Urban Development Grant for Multi-Purpose Facility for AIDS/HIV Related Services  
Role: Co-Investigator

Abbott Pharmaceuticals                      PI: Larking, JA                      1996  
Life to date earnings: \$10,000  
In vitro Susceptibility of HIV-1 Isolates to Ritonavir (ABT-538). Purpose Sample local HIV isolates for resistance by genotype.  
Role: Co-Investigator

Human Rehabilitative Services                      PI: Sinnott, J                      1995-1996  
Project # DHS-BRH  
Life to date earnings: \$12,000  
Ryan White Title IX: Primary Care Approach to HIV Management  
Role: Co-Investigator

Human Rehabilitative Services                      PI: Sinnott, J                      1993-1994  
Project # BRH-890024-01-0  
Life to date earnings: \$113,615  
Ryan White Title IX: Multidisciplinary Team Enhanced AIDS Management Models  
Role: Co-Investigator

FL AIDS Education Training Network PI: Sinnott, J 1993  
Project # DHHS-BHP No. 1 D35 PE 00101-02, Subcontract A  
Life to date earnings: \$20,000  
The Medical Student History and Physical Examination of the AIDS Patient: Focus on Attitudes and Techniques  
Role: Co-Investigator

SCS001F PI: Nadler, JP 1993 - 1994  
Life to date earnings: \$90,000  
Clinical Investigational Protocol for OMNI-SAI TM Saliva Collection Device, University of South Florida, Division of Infectious and Tropical Diseases.  
Role: Co-Investigator

Cortech CP-0127-92-002 PI: Rumbak, M Jun 1993-Oct 1993  
Life to date earnings: \$66,000  
Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Three doses of CP-0127 and Placebo in Patients with Presumed Sepsis and the Systemic Inflammatory Response Syndromes (SIRS).  
Role: Co-Investigator

Health Resources and Service Administration PI: Knox, M 1992-2004  
Project DHHS-BHP No. 1 D35 PE 00101-02A  
Award amount: \$32,000  
USF Center for HIV Education and Research  
Role: Co-Investigator

US Public Health Service PI: Knox, M 1992-2013  
Subagreement 5840 052 K O  
Award amount: \$960,000  
University of South Florida Center for HIV Education and Research  
Role: Co-Investigator

PI: Rosemurgy, A 1992 - 1993  
Funded amount: \$16,800  
A Prospective, Multicenter, Randomized Comparison of Fluconazole and Placebo in the Treatment of Funguria.

Lederle PI: Toney, JF 1992  
Funded amount: \$39,213  
The Use of Piperacillin/Tazobactam and Tobramycin vs. Imipenem and Tobramycin in Septicemia.  
Role: Co-Investigator

Ortho PI: Toney, JF 1992  
Funded amount: \$40,615  
Comparison of Cefaclor vs. Ofloxacin in Pneumonia/Bronchitis.  
Role: Co-Investigator

Roerig Pharmaceuticals PI: Toney, JF 1992  
Funded amount: \$7,000  
Ampicillin/Sulbactam in the Treatment of Urinary Tract Infections.  
Role: Co-Investigator

Hoechst-Roussel Funded amount: \$37,500 The Use of Pentoxifylline vs. Placebo in the Prophylaxis of Amphotericin B-induced Nephrotoxicity. Role: Co-Investigator	PI: Greene, JN	1992
Merrel Dow Funded amount: \$33,000 The Use of Teicoplanin vs. Ceftriaxone in Skin Infections Role: Co-Investigator	PI: Toney, JF	1992
Centocor Corporation Funded amount: \$15,000 A Prospective Double Blind Randomized study of HA-1A anti Endotoxin Efficacy in Septic Shock Trial. Role: Co-Investigator	PI: Rosemurgy, AT	1992
Abbott Laboratories Funded amount: \$33,000 Temafloracin vs. Imipenem in the Treatment of Skin Infections. Role: Co-Investigator	PI: Toney, JF	1992
Fujisawa Funded amount: \$61,593 The Use of Ceftriaxone vs. Cefodizime in the Treatment of Pneumonia. Role: Co-Investigator	PI: Toney, JF	1992
US Public Health Service Project R067 Award amount: \$18,000 HIV Health Care Cost in Hospitalized Patients	PI: Holt, DA	1991-1998
US Public Health Service Project R067, Westat Research Award amount: \$10,000 HIV Health Care Cost in Hospitalized Patients	PI: Holt, DA	1991-1992
Centocor Corporation Funded amount: \$80,000 Randomized, Double Blind Study of Monoclonal Anti-Tumor Necrosis Factor Therapy in Septic Shock. Role: Co-Investigator	PI: Sinnott, JT	1991 - 1992
Glaxo Pharmaceuticals Funded amount: \$20,000 An Open-Label Multicenter Study Evaluating Treatment with IV Cefuroxime Followed by Oral Cefuroxime in Patients with Community Acquired Pneumonia. Role: Co-Investigator	PI: Dillon, DR	1990
Glaxo Pharmaceuticals Funded amount: \$20,000 A Prospective, Randomized, Investigator-blinded, Multicenter, Comparative Study of Ceftazidime BID vs. TID in Hospitalized Patients with Lower Respiratory Infections and/or Septicemia Due to Susceptible Pathogenic Organisms. Role: Co-Investigator	PI: Cancio, MR	1990



PI: Chmel, H 1988  
Ciprofloxacin in the Management of Febrile Granulocytopenic Cancer Patients with Suspected Infection  
Role: Co-Investigator

PI: Chmel, H 1988  
Multicenter Comparison of Fluconazole and Amphotericin-B as Maintenance Treatment for the Prevention of Relapse of Cryptococcal Meningitis in Patients with Acquired Immunodeficiency Syndrome.  
Role: Co-Investigator

PI: Chmel, H 1988  
Multicenter Comparison of Fluconazole and Amphotericin-B as Treatment for Acute Cryptococcal Meningitis.  
Role: Co-Investigator

PI: Yangco, BG 1987  
A Randomized Open Study of Teicoplanin vs. Cefazolin in the Treatment of Moderate to Severe Skin and Soft Tissue Infections Caused by Gram-Positive Bacteria.  
Role: Co-Investigator

PI: Yangco, BG 1987  
An Open Study of the Efficacy, Safety, and Tolerability of Imipenem/Cilastatin Administered Intravenously then Intra- muscularly for the Treatment of Patients with Urinary Tract Infections.  
Role: Co-Investigator

PI: Yangco, BG 1987  
A Randomized, Controlled Study of Enoxacin vs. Cefotaxime in Patients with Skin and Skin Structure Infections.  
Role: Co-Investigator subinvestigator

PI: Yangco, BG 1987  
Treatment of Community Acquired Pneumonia with Intravenous Trospsectomycin.  
Role: Co-Investigator

PI: Chmel H 1987  
Ampicillin Sulbactam in the Treatment of Acute Episodes of Urinary Tract Infections of Ampicillin-Resistant Bacterial Etiology.  
Role: Co-Investigator

PI: Chmel H 1987  
Multicenter Trial to Determine the Safety and Efficacy of Antiendotoxin Antibody XOMEN-E5 in the Treatment of Patients with Suspected Gram-Negative Bacteremia or Endotoxemia.  
Role: Co-Investigator

### **Short Term Goals:**

Romark Labs Co-PI: Rossignol/Casale/Morano 2017 - present  
Funding pending: Travel/Research Costs  
Investigation of NT-300 (tizosanide) Effects on Zika Virus en Vivo: Pre- and Post-exposure prophylaxis and treatment.  
DOH/Panama Collaborators: Holt/Sinnott/Menezes Co-I

**Service:**

**Community Positions:**

Executive Committee, Hillsborough County Medical Association, 2003-Present

Member, School Readiness Coalition, 2002-Present

Member, H. Lee Moffitt Cancer Center & Research Institute Lifetime Cancer Screening Center, Inc. (Board of Directors), 2001-2004

Member, Institute of Medicine, Public Health Survey, 1998-2000

Member, United Way, Success by 6 Initiative, 1998-2000

Member, Hillsborough Tomorrow, School Readiness Workgroup, 1998-1999

Founding Member, Healthy Kids of Hillsborough County, 1997-Present

President, The Kids Health Care Foundation, 1997-Present

Member, West Central Public Health Alliance, 1997-Present

Member, Hillsborough County Medical Association: Health Planning Committee,

Disaster Preparedness, 1997-Present

Member, State of Florida, AIDS Drug Assistance Workgroup, 1997-2003

Member, Human Services Council of Hillsborough, 1997-2001

Director, SunCoast AIDS Network, 1997

Chairman, Provider Subcommittee, Tampa General Hospital, Tampa, FL, 1997

Member, Managed Care Marketing Assessment (Steering Committee), Tampa General Hospital, Tampa, FL, 1997

Florida Association of County Health Officers, Treasurer 1997-2002; Vice President 2002-2004; President 2004-2006

Member, State of Florida, Pregnancy-Associated Mortality Review Team, 1996-Present

Member, Healthy Start Coalition of Hillsborough County (Board of Directors), 1996-Present

**Associated Community Activities:**

Black Leadership Commission on AIDS of Tampa Bay, 2009-2013

Member, AIDS Coordinating Council, Hillsborough County, Tampa, Florida, 1992-1999

Co-founder, University of South Florida and District Volunteer AIDS Clinic, Tampa, Florida 1992-1996

Member, Advisory Board, Tampa AIDS Network, Tampa, Florida, 1991-2001

Numerous assorted Media Interviews on AIDS, Transplantation and Infectious Diseases  
Tampa, Florida, 1988-Present

Advisor, Hospice of Hillsborough, Inc., Tampa, Florida, 1989-1995

Member, Tampa Bay Medical AIDS Task Force, Tampa, Florida, 1988-1992

**Committees:**

Member, USF Physicians Group (USFPG) Board of Directors, 2015 - 2017

Member, Utilization Management Committee, Tampa General Hospital, Tampa, Florida,  
2013 – 2020

Member, Sepsis Committee, Tampa General Hospital, Tampa, Florida, 2013-2020

Member, Medical Executive Committee, Tampa General Hospital, Tampa, Florida, 2013 -  
2014

Chair, Florida TB System of Care Committee, June 2012- 2015

Member, Health Care Advisory Board (HCAB) Management Sub-Committee, Tampa  
General Hospital, Tampa, Florida, 2012 - present

Member, Medical Student Selection Committee, University of South Florida, Morsani  
College of Medicine, 2010-2018

Member, Physician Benefits Committee, University of South Florida, 2007-2010

Member, Hillsborough Community College Golf Committee, 2007-2011

Member, Board of Hillsborough Community College Foundation, 2006-2014

Member, Financial Oversight Committee, University of South Florida, 2006-2010

Member, Children's Board of Hillsborough County Advocacy Committee, 2003-Present

Chairman, Pharmacy and Therapeutics Committee, Tampa General Hospital, Tampa,  
Florida, 1999-2020

Member, Port Tampa Planning Board, 1998-2014

Member, USF College of Public Health MPH/MBA Advisory Committee, 1998-2001

Member, Healthcase, Quality Improvement Committee, 1997-1999

Member, Hillsborough County, School Health Services Advisory Committee, 1997-Present

Member, State Department of Children & Families, Health & Human Services Board (Health Sub-Committee), 1997

Member, State of Florida, Pregnancy-Associated Mortality Review Team, 1996-Present

Representative, Morsani College of Medicine, Deans Task Force on Hospital Exposures, University of South Florida, Morsani College of Medicine, 1993-1996

Representative, Morsani College of Medicine, University of South Florida Faculty Senate, University of South Florida Tampa, Florida, 1993-1994

Representative, Committee on Committees Faculty Senate, University of South Florida, Faculty Senate, Tampa, Florida, 1993-1994

Member, Tuberculosis Task Force, Tampa General Hospital, Tampa, Florida, 1992-1996

Chair, Committee on Fellowship Evaluation, Division of Infectious Diseases and Tropical Medicine, Department of Internal Medicine, University of South Florida, 1992-Present

Member, Committee on Student Affairs, University of South Florida, Morsani College of Medicine, Tampa, Florida, 1992-1996

Member, Occupational Health Advisory Committee, Tampa General Hospital, Tampa, Florida, 1992-1995

Member, Pharmacy and Therapeutics Committee, Tampa General Hospital, Tampa, Florida, 1989-Present

Chair, Infection Prevention and Control Committee, Tampa General Hospital, Tampa, Florida, 1988-1994, 2010-Present

Member, Infection Prevention and Control Committee, Tampa General Hospital, Tampa, Florida, 1988-1996, 2010-Present

Chair, AIDS Task Force, Tampa General Hospital, Tampa, Florida, 1988-1996

**Society Memberships:**

Fellow, Infectious Disease Society of America (IDSA), 2017 - present

Member, Florida Infectious Disease Society (Executive Board), 2013 - Present

President, Florida Public Health Association 2009 – 2010

President, Florida Association of County Health Officers, 2004-2006

Vice President, Florida Association of County Health Officers, 2002

Secretary, Florida Association of County Health Officers, 1999

Member, Hillsborough County Medical Association 1998-Present

Member, Florida Public Health Association, 1996-Present

Member, Southern Medical Association, 1992-2002

Member, Society for Hospital Epidemiology 1991-2001

Member, Infectious Disease Society of America, 1991-2002

Fellow, American College of Physicians, 1993

Member, American Society for Microbiology 1988-2003

Member, American Medical Association, 1988-2014